Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein

Shijian Zhang^{1*}, Eden P. Go^{2*}, Haitao Ding³, Saumya Anang¹, John C. Kappes^{3,4},
Heather Desaire² and Joseph Sodroski^{1,5**}

¹Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
Department of Microbiology, Harvard Medical School, Boston, MA 02215, USA

²Department of Chemistry, University of Kansas, Lawrence, KS 66049, USA

³Department of Medicine, University of Alabama at Birmingham, AL 35294, USA

⁴Birmingham Veterans Affairs Medical Center, Research Service,
Birmingham, AL 35233, USA

⁵Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of
Public Health, Boston, MA 02215, USA

*These authors contributed equally to the research reported in this manuscript.

**Corresponding author:
Joseph G. Sodroski, M.D.
Dana-Farber Cancer Institute
450 Brookline Avenue, CLS 1010

Boston, MA 02215

Phone: 617-632-3371 Fax: 617-632-4338

Email: joseph_sodroski@dfci.harvard.edu

Abstract word count: 249

Running title: SARS-CoV-2 spike glycosylation and disulfide bonding

Keywords: COVID-19, SARS-CoV-2, coronavirus, viral protein, spike glycoprotein, glycosylation, disulfide, Golgi, virus entry, membrane protein

ABSTRACT

The SARS-CoV-2 coronavirus, the etiologic agent of COVID-19, uses its spike (S) glycoprotein anchored in the viral membrane to enter host cells. The S glycoprotein is the major target for neutralizing antibodies elicited by natural infection and by vaccines. Approximately 35% of the SARS-CoV-2 S glycoprotein consists of carbohydrate, which can influence virus infectivity and susceptibility to antibody inhibition. We found that virus-like particles produced by coexpression of SARS-CoV-2 S, M, E and N proteins contained spike glycoproteins that were extensively modified by complex carbohydrates. We used a fucose-selective lectin to enrich the Golgi-resident fraction of a wild-type SARS-CoV-2 S glycoprotein trimer, and determined its glycosylation and disulfide bond profile. Compared with soluble or solubilized S glycoproteins modified to prevent proteolytic cleavage and to retain a prefusion conformation, more of the wild-type S glycoprotein N-linked glycans are processed to complex forms. Even Asn 234, a significant percentage of which is decorated by high-mannose glycans on soluble and virion S trimers, is predominantly modified in the Golgi by processed glycans. Three incompletely occupied sites of O-linked glycosylation were detected. Viruses pseudotyped with natural variants of the serine/threonine residues implicated in O-linked glycosylation were generally infectious and exhibited sensitivity to neutralization by soluble ACE2 and convalescent antisera comparable to that of the wild-type virus. Unlike other natural cysteine variants, a Cys15Phe (C15F) mutant retained partial, but unstable, infectivity. These findings enhance our understanding of the Golgi processing of the native SARS-CoV-2 S glycoprotein carbohydrates and could assist the design of interventions.

INTRODUCTION

The recently emerged severe acute respiratory sndrome coronavirus (SARS-CoV-2) is responsible for the ongoing pandemic of COVID-19, a respiratory disease with an estimated 2-5% mortality (1-7). The SARS-CoV-2 spike (S) glycoprotein mediates the entry of the virus into the host cell and influences tissue tropism and pathogenesis (8-13). The S glycoprotein trimer in the viral membrane is the target for neutralizing antibodies, which are important for vaccine-induced protection against infection (9, 11, 12, 14-18). Monoclonal neutralizing antibodies directed against the S glycoprotein are being evaluated as treatments for SARS-CoV-2-infected individuals (15, 19-27). In the virus-producing cell, the S glycoprotein is synthesized in the endoplasmic reticulum, where it assembles into trimers and is initially modified by high-mannose glycans (28, 29). Each of the three SARS-CoV-2 S glycoprotein protomers possesses 22 canonical sequons for N-linked glycosylation (11, 30-36). Coronavirus virions bud into the endoplasmic reticulum-Golgi intermediate compartment (ERGIC), and S glycoprotein trimers on the surface of these virus particles are thought to be processed further during trafficking through the Golgi complex (29, 37-40). In the Golgi, some of the glycans on the S glycoprotein are modified to complex carbohydrates; in addition, the trimeric S glycoprotein is cleaved by furin proteases into S1 and S2 glycoproteins, which associate non-covalently in the virus spike (27-36). During virus entry, the S1 subunit binds the receptor, angiotensin-converting enzyme 2 (ACE2) (9, 11-13, 41-43). The S2 subunit is further processed by host proteases and undergoes extensive conformational changes to mediate the fusion of the viral and target cell membranes (43-47). Following the insertion of the S2 fusion peptide into the host cell membrane, the interaction of two

helical heptad repeat regions (HR1 and HR2) on the S2 subunit brings the viral and cell membranes into proximity (44).

The SARS-CoV-2 S glycoprotein trimer is modified by glycosylation, which in other coronaviruses has been suggested to modulate accessibility to neutralizing antibodies as well as host proteases involved in S processing (11, 13, 30-32, 48, 49). Glycans camouflage S glycoprotein peptide epitopes, shielding them from potentially neutralizing antibodies. Glycans can also contribute to epitopes for antibody recognition; for example, the s309 neutralizing antibody interacts with the glycan on Asn 343 of the SARS-CoV-2 S glycoprotein (50).

Virus entry inhibitors and therapeutic or prophylactic neutralizing antibodies must recognize the mature SARS-CoV-2 spike with its natural glycan coat, as it exists on the viral membrane. The glycosylation of the SARS-CoV-2 spike has been studied using soluble or detergent-solubilized versions of the uncleaved S glycoprotein trimer, modified to retain a pretriggered conformation (30, 33-36, 51). Fewer studies of the glycosylation of S glycoproteins on SARS-CoV-2 virion preparations have been conducted (52, 53). Experience with human immunodeficiency virus (HIV-1) indicates that native, membrane-anchored viral envelope glycoproteins can exhibit glycosylation profiles that differ from those of soluble glycoprotein trimers (54-57). Here, we elucidate the glycosylation and disulfide bonding profile of a wild-type SARS-CoV-2 S glycoprotein trimer, and evaluate the importance of naturally occurring variation in O-linked glycans and disulfide bonds. This information enhances our understanding of the

complete, functional SARS-CoV-2 S spike and could assist the development and improvement of efficacious therapies, including monoclonal antibodies, and vaccines.

RESULTS

Characterization of SARS-CoV-2 S glycoproteins in cell lysates and virus-like particles

We evaluated the wild-type SARS-CoV-2 S glycoprotein expressed alone or in combination with the viral membrane (M), envelope (E) and nucleocapsid (N) proteins, which direct the formation of virus-like particles (VLPs) (58, 59). In the absence of M, E and N proteins, low levels of the S glycoprotein, presumably in extracellular vesicles, were detected in particles prepared by centrifugation of the supernatants of transiently expressing 293T cells (Figure 1A-C). Coexpression of the M, E and N proteins, particularly in combination, resulted in an increase in the level of S glycoprotein in the supernatant pellets. Both uncleaved S and cleaved (S1 and S2) glycoproteins were detected in the particles prepared from the cell supernatants (Figure 1A and B). Two forms of the uncleaved S glycoprotein were detected in the pelleted particles: 1) a faster-migrating form modified by Endoglycosidase Hf (Endo Hf)-sensitive (high-mannose and/or hybrid) glycans, and 2) a more slowly migrating form modified by Endo Hf-resistant (complex) glycans (Figure 1B). Coexpression of the E glycoprotein resulted in an increase in the ratio of complex:high-mannose glycans in the uncleaved S glycoprotein in the pelleted particles. The vast majority of the cleaved S1 and S2 glycoproteins in the pelleted VLPs was resistant to Endo Hf digestion. Thus, in the presence of SARS-CoV-2 M, E and N proteins, the uncleaved and cleaved S glycoproteins on VLPs are largely modified by complex carbohydrates.

Expression and purification of the SARS-CoV-2 S glycoprotein

To study the native SARS-CoV-2 S glycoprotein in greater detail, we established a stable 293T cell line (293T-S) that expresses the wild-type SARS-CoV-2 S glycoprotein under the control of a tetracycline-inducible promoter (29). To facilitate purification, a carboxy-terminal 2xStrep affinity tag was added to the S glycoprotein, which was otherwise wild-type in sequence (29). Treatment of the 293T-S cells with doxycycline resulted in the expression of the S glycoprotein, which was cleaved into the S1 exterior and S2 transmembrane glycoproteins (Figure 2A). The expressed S glycoproteins mediated the formation of syncytia when human ACE2 (hACE2) was transiently coexpressed in the 293T-S cells (Figure 2A). The expressed S glycoproteins supported infection of 293T-hACE2 cells by a pseudotyped vesicular stomatitis virus (VSV) vector (Figure 2B). Nearly all of the S glycoproteins incorporated into VSV pseudotypes were cleaved (Figure 2B).

For purification of the SARS-CoV-2 S glycoprotein, we evaluated several detergents as well as styrene-maleic acid (SMA) copolymers for their ability to extract the S glycoproteins from 293T-S membranes (60-65). NP-40, Triton X-100 and Cymal-5 solubilized the S glycoproteins more efficiently than lauryl maltyl neopentyl glycol (LMNG) or SMA (Figure 3A). The solubilized S glycoproteins migrated on Blue Native gels at a size consistent with trimers (Figure 3B). Strep-Tactin purification of the cleaved S1/S2 complexes as well as the uncleaved S glycoproteins in Cymal-5 solutions was slightly more efficient than in the other detergents; therefore, we used Cymal-5 to extract the S glycoproteins for purification.

Both uncleaved and cleaved SARS-CoV-2 S glycoproteins are incorporated into virus-like particles (VLPs) formed as a result of expression of the SARS-CoV-2 M, E and N proteins (59) (Figure 1). The S glycoproteins in VLPs are extensively modified by complex carbohydrates, indicating passage through the Golgi compartment. Therefore, we enriched the mature, Golgi-resident S glycoproteins by sequentially using Strep-Tactin and Aleuria aurantia lectin (AAL) to purify the S glycoproteins from the membranes of 293T-S cells (Figure 3C). AAL recognizes fucose, which is added to a subset of complex glycans in the Golgi apparatus (66-69). The purified S glycoproteins consisted of approximately 25% uncleaved and 75% cleaved (S1 and S2) glycoproteins (Figure 3D).

Disulfide and glycosylation analysis of the purified S glycoproteins

The disulfide bond topology of the purified S glycoproteins was determined by identifying disulfide-linked peptides from the tryptic digests of the S glycoprotein preparation by mass spectrometry (MS) (Figures 4 and 5). The S1 glycoprotein begins at an N-terminal glutamine (residue 14) that has undergone condensation to form pyroglutamine. The same N-terminus has been observed for secreted, soluble forms of uncleaved SARS-CoV-2 S glycoprotein trimers (33). Ten disulfide bonds in S1 and five disulfide bonds in S2 were mapped. The cysteine residues paired in the mapped disulfide bonds are consistent with those defined by structural analyses (11, 13, 70). We also observed an alternative disulfide bond between Cys 131 and Cys 136 (Figure 5); in current S glycoprotein structures (11, 13, 70), these N-terminal domain cysteine residues are 12-15 Å apart and therefore are unable to form a disulfide bond without a

change in conformation. Apparently, a fraction of the expressed S glycoproteins tolerates some plasticity in the N-terminal domain.

The glycan profile and glycosylation site occupancy of the 22 potential N-linked glycosylation sites were determined using an integrated glycopeptide-based MS approach described previously (54, 55, 71). With the exception of one site, Asn 1074, all of the N-linked glycosylation sites on this protein were fully occupied with glycans (Table 1). Asn 1074 was detected as partially occupied, although the unoccupied form is just one of over fifty different forms present at this site.

A pictorial description of the glycosylation profile of this protein is shown in Figure 6. In sum, 826 unique N-linked glycopeptides were detected, along with 17 O-linked glycopeptides. This glycosylation coverage is more in-depth than early reports, where the number of unique glycoforms detected was more typically in the 100-200 range (30, 33, 35). Furthermore, this analysis provides the first report of O-linked glycosylation at 7 glycosylation sites: S659, S673, T676, S680, T696, T1160, and S1170.

As can be seen in Figure 6, processed glycoforms predominated at each N-linked glycosylation site and, as shown in Figure 7A, these complex forms were highly, but not exclusively, fucosylated. Additionally, even though each glycosylation site was heavily processed in the Golgi, the sialic acid content varied across the protein sequence. Some sites, like N61 and N603 had no sialylated glycoforms detected, while

most of the sites in the S2 protein, particularly those nearest the C terminus, were abundantly sialylated. Finally, as shown in Figure 7B, a number of O-linked glycoforms were detected.

The vast majority of the N-linked glycans on the Golgi-enriched, wild-type SARS-CoV-2 S glycoprotein expressed in 293T cells were processed to complex glycans. In Figure 8, we compare our results with available glycosylation analyses of soluble or solubilized SARS-CoV-2 S glycoproteins. These include wild-type S glycoproteins purified from SARS-CoV-2 virions, as well as soluble and full-length S glycoprotein trimers modified to inhibit furin cleavage and to stabilize a prefusion conformation (30, 33, 34, 36, 51-53). The glycans on individually expressed SARS-CoV-2 S1 and S2 glycoproteins have also been analyzed (35). All studies agree that complex carbohydrates are found on most of the N-linked glycan sites on SARS-CoV-2 S glycoprotein trimers, as well as on recombinant soluble S1 and S2 glycoproteins. However, the extent of N-linked glycan processing in our study is greater than that seen for either soluble S glycoprotein trimers or for modified (cleavage-defective, proline-substituted) S glycoprotein variants (30, 33, 34, 36, 51). The glycosylation profile of our Golgi-enriched S glycoprotein preparation most closely resembles that of S glycoproteins purified from SARS-CoV-2 virions propagated in Vero cells (Figure 8). However, in our S glycoprotein preparation, Asn 234 in the S1 N-terminal domain is mostly processed, whereas high-mannose glycans are retained at this site in the other characterized S glycoprotein variants. The highest composition of high-mannose glycans in our study mapped to a glycopeptide containing two potential N-linked

glycosylation sites at Asn 709 and Asn 717. Although we cannot precisely assign a glycan composition at either site, our result is consistent with observations on soluble/modified S glycoproteins suggesting that one or both of these sites is occupied by a significant percentage of high-mannose glycans (30, 33, 34). The location of these glycans in a heavily glycosylated region near the base of the S1 subunit may limit the access of glycosylation enzymes and predispose to the retention of high-mannose glycans (Figure 9).

O-linked glycosylation of two S1 glycopeptides and two S2 glycopeptides was detected (Figure 7B). Potential candidates for O-glycosylated residues include Thr 323, Ser 325, Ser 659, Ser 673, Thr 676, Thr 678 and Ser 680 in S1, and Thr 696, Thr 1160 and Ser 1170 in S2. O-linked glycosylation at Thr 323/Ser 325 was reported for soluble S glycoproteins and virion S glycoprotein trimers, but with low occupancy; in some cases, less than 1% of the residues were modified (33, 35, 36, 53). In this study, the occupancy rate for these two sites is also around 1% (Table 1). Thr 678 has also been reported to be O-glycosylated in soluble and virion S glycoproteins, with higher occupancy than that for Thr 323/Ser 325 (36, 53). In our study, the peptide containing Ser 659, Ser 673, Thr 676, Thr 678 and Ser 680 was found to be occupied by at least one O-linked glycan at a level of about 5%.

SARS-CoV-2 S glycoprotein expression in a cell line with defective glycosylation

GALE/GALK2 293T cells defective for O-linked glycosylation have been established (73). Both the wild-type SARS-CoV-2 S glycoprotein and the prevalent

D614G variant S glycoprotein (29, 74-76) were expressed in 293T cells and in the GALE/GALK2 293T cells. Both the S1 and S2 glycoproteins of the wild-type and D614G SARS-CoV-2 strains migrated faster when expressed in the GALE/GALK2 293T cells compared with the migration of these glycoproteins expressed in 293T cells (Figure 10A). Digestion of the glycoproteins with PNGase F revealed that the observed differences in S1 migration could be explained by differences in N-linked glycosylation. PNGase F digestion of the S2 glycoprotein resulted in 60- and 63-kD products. The 60-kD PNGase F-produced S2 proteins expressed in wild-type and GALE/GALK2 293T cells migrated similarly, ruling out a significant level of O-linked glycosylation. The 63-kD PNGase F S2 product potentially is O-glycosylated, as it migrated faster when synthesized in the GALE/GALK2 293T cells. However, the 63-kD product observed after PNGase F digestion was minimally affected by further treatment with O-glycosidase + neuraminidase. Moreover, no significant difference in the migration of the untreated S1 and S2 glycoproteins was observed after O-glycosidase + neuraminidase treatment. We note that the Core 1 O-linked glycans detected on the purified S glycoproteins should be digestible by O-glycosidase + neuraminidase, as was shown on a control substrate, fetuin (Figure 10B). Taken together, these results indicate that O-glycan occupancy is low on the SARS-CoV-2 S glycoproteins expressed in 293T cells. Variation in other post-translational modifications, including N-linked glycosylation, apparently accounts for most of the observed differences in the migration of S1 and S2 glycoproteins expressed in wild-type and GALE/GALK2 293T cells. When the S glycoproteins produced in GALE/GALK2 293T cells were used to pseudotype vesicular stomatitis virus (VSV) vectors, the resulting viruses exhibited lower infectivity than

viruses made with S glycoproteins produced in 293T cells (data not shown). These results suggest that differences in the post-translational modifications of S glycoproteins produced in 293T and GALE/GALK2 293T cells may influence S glycoprotein function. As only a fraction of the S glycoprotein is modified by O-linked glycans in 293T cells, differences in O-linked glycosylation are unlikely to explain the observed reduction in the infectivity of VSV(S) pseudotypes produced in GALE/GALK2 293T cells.

Natural variants of SARS-CoV-2 S glycoproteins

Rare natural variants of SARS-CoV-2 S glycoproteins exhibit substitutions at one of the cysteine residues, potentially compromising the formation of particular disulfide bonds (77, 78). We wished to assess the impact of these substitutions on S glycoprotein expression, processing and function. The C15F change eliminates the Cys 15-Cys 136 disulfide bond in the S1 N-terminal domain. Despite this alteration, the C15F S glycoprotein was proteolytically processed nearly as efficiently as the wild-type S glycoprotein and exhibited wild-type association of the S1 and S2 subunits (Figure 11 and Table 2). The infectivity of VSV vectors pseudotyped with the C15F S glycoproteins was approximately 31% of that of virus pseudotyped with the wild-type S glycoproteins. However, after freeze-thawing, the relative infectivity of the C15F mutant virus decreased dramatically (data not shown). Apparently, the Cys 15-Cys 136 disulfide bond is not absolutely essential for S glycoprotein function, but may contribute to the stability of the functional spike. By contrast, the C301F and C379F changes, which eliminate the Cys 291-Cys 301 and Cys 379-Cys 432 disulfide bonds respectively located in the S1 N-terminal domain and receptor-binding domain, resulted in S

glycoproteins that were not processed into S1 and S2 glycoproteins (Figure 11 and Table 2). Viruses pseudotyped with the C301F and C379F S glycoproteins exhibited very low levels of infectivity. Thus, of these rare cysteine variants of the SARS-CoV-2 S glycoprotein, only one (C15F) allows partial, but unstable, infectivity.

To evaluate the potential O-linked glycosylation of the SARS-CoV-2 S glycoprotein, several of the threonine and serine residues implicated in our MS study were altered to residues found in natural SARS-CoV-2 variants (77, 78). The T323I, S676I and S1170F mutants were processed nearly as efficiently as the wild-type S glycoprotein, and exhibited good subunit association (Figure 11A and Table 2). The 63-kD S2 glycoprotein band seen in PNGase F-treated lysates from 293T cells expressing the wild-type S glycoproteins was not evident in lysates from cells expressing the S1170F mutant (Figure 11B and C). As the S1170F change does not alter a potential N-linked glycosylation site, it apparently affects other post-translational modifications; as discussed above, resistance of the 63-kD PNGase F product to O-glycosidase appears to rule out modification by Core 1 or Core 3 O-glycans (Figure 11C). The S676I and S1170F mutants supported the entry of VSV pseudotypes as efficiently as the wild-type S glycoprotein (Table 2). The T323I-pseudotyped viruses infected cells with approximately 41% of the efficiency of viruses pseudotyped with the wild-type S glycoproteins, but the infectivity of these viruses decreased further upon freeze-thawing. The S673I mutant was processed inefficiently and only supported the infection of pseudotyped VSV vectors at a very low level.

We examined the sensitivity of the two most replication-competent S glycoprotein mutants, T676I and S1170F, to neutralization by soluble ACE2 (sACE2) and sera from convalescing SARS-CoV-2-infected individuals. No significant differences in the neutralization sensitivity of the wild-type and mutant viruses were observed (Figure 12).

DISCUSSION

As the extensive glycosylation of the spike (S) glycoprotein can potentially influence SARS-CoV-2 infectivity and sensitivity to antibody inhibition, an understanding of the glycosylation profile of the native S glycoprotein trimer is valuable. Glycosylation of the SARS-CoV-2 S glycoprotein can apparently be influenced by subcellular localization and the coexpression of viral proteins. Because proteolytic activation of the S glycoprotein can occur at the cell surface or in endosomal compartments during virus entry, the uncleaved S glycoprotein, as well as the cleaved S glycoproteins, on virions can support virus infection (29, 45-47). Both uncleaved and cleaved S glycoproteins on virions are extensively modified by complex carbohydrates, indicating passage through the Golgi complex (29, 69, 79). We found that coexpression of the SARS-CoV-2 E protein led to a further enrichment of complex glycans on the uncleaved S glycoprotein on VLPs. These observations provided a rationale for focusing on the Golgi-resident S glycoproteins. By including a lectin, AAL, that recognizes fucose in the purification scheme, we attempted to increase the representation of S glycoproteins that passed through the Golgi complex, where fucosylation occurs (66-69). This purification strategy allowed an evaluation of the glycan composition of a Golgi-enriched subset of the S glycoproteins synthesized in the expressing cell; it is conceivable that less processed forms of the S glycoproteins might also be present on virions, depending on host cell type, production levels and VLP characteristics.

SARS-CoV-2 S glycoproteins produced for use as vaccine immunogens have been designed to allow secretion of soluble trimers, to inhibit furin cleavage, and to

stabilize prefusogenic conformations (11, 13, 51, 80-84). The glycosylation profile of virion S glycoproteins and several of these modified S glycoproteins has been characterized (30, 33, 36, 51, 70, 71). Our results agree with the overall predominance of complex carbohydrates of the SARS-CoV-2 S glycoprotein trimer seen in these previous studies. The glycosylation profile of our S glycoprotein preparation most closely resembles that of the S glycoproteins purified from SARS-CoV-2 virions propagated in Vero cells (52). However, compared with these and the other characterized trimers, the wild-type S glycoproteins purified in our study exhibited more glycan processing. The inclusion of a fucose-specific lectin in our purification scheme may have increased the representation of S glycoproteins that have passed through the Golgi, where complex carbohydrates are added (69). Soluble or virion-associated S glycoproteins passing through the Golgi may be processed less efficiently than our Golgi-enriched membrane-anchored S glycoproteins. The observed differences are particularly noteworthy for the Asn 234 glycan, which is predominantly of the high-mannose type in the soluble/modified S glycoproteins, but mostly processed in the wild-type S glycoprotein that we studied. Asn 234 in the S1 N-terminal domain is near the receptor-binding domain, and molecular dynamics simulations have suggested that the N234 glycan can modulate the conformational changes that the receptor-binding domain undergoes in the process of binding ACE2 (85). Moreover, changes in Asn 234 have been reported to affect virus sensitivity to several neutralizing antibodies (86). The particular types of glycans modifying Asn 234 might influence the binding and/or generation of neutralizing antibodies directed against nearby epitopes. Whatever its function, our results indicate that the N234 glycan is accessible on the unliganded wild-

type S glycoprotein trimer for modification to complex carbohydrates. Specific down-selection of the N234 high-mannose glycans by AAL purification is possible but not likely, given the abundance of multiple fucose-containing glycans on all S glycoforms produced in the 293T-S cells.

O-linked glycans were detected on four glycopeptides in the purified S glycoprotein. Changing Thr 323, Thr 676 and Ser 1170 to those amino acid residues found in less common natural SARS-CoV-2 variants resulted in entry-competent S glycoproteins. However, the infectivity of the T323I mutant was more sensitive to freeze-thawing than that of viruses pseudotyped with the wild-type S glycoprotein. On the other hand, even though the S1170F change altered post-translational modification of the S2 glycoprotein, this mutant exhibited wild-type levels of infectivity and resistance to freeze-thawing. Alteration of Thr 676 or Ser 1170 did not significantly change the sensitivity of the pseudotyped viruses to neutralization by sACE2 or convalescent-phase sera.

Of the three naturally observed variants in S glycoprotein cysteine residues, a change in Cys 15 was compatible with an entry-competent S glycoprotein. This implies that the disulfide bond between Cys 15 and Cys 136 within the N-terminal domain is not absolutely required for folding and function of the SARS-CoV-2 S glycoprotein. However, we noted that the infectivity of the C15F mutant virus was compromised after freeze-thawing more than that of the wild-type virus. Apparently, some flexibility in the N-terminal domain can be tolerated in functional S glycoprotein trimers, although the

ability of the virus to withstand environmental stress may be affected. Of note, some of the expressed S glycoproteins formed a disulfide bond between Cys 131 and Cys 136, and therefore lacked two of the canonical disulfide bonds (Cys 15-Cys 136 and Cys 131-Cys 166) in the N-terminal domain. Such S conformers, with presumably less stable N-terminal domains, might potentially contribute to viral pathogenesis or to evasion of the host immune response.

These studies should assist understanding of the nature and contribution of glycans on the wild-type SARS-CoV-2 S glycoprotein trimer and provide some insight into the impact of natural variation in sites that are glycosylated or disulfide bonded.

EXPERIMENTAL PROCEDURES

Reagents

Trizma[®] hydrochloride, Trizma[®] base, ammonium bicarbonate, urea, tris(2-carboxyethyl) phosphine hydrochloride (TCEP), iodoacetamide (IAM), ethanol, 4-vinylpyridine (4-VP), and glacial acetic acid were purchased from Sigma. Other reagents used in this study included optima LC/MS grade acetonitrile, water, formic acid (Fisher Scientific), sequencing grade trypsin (Promega), chymotrypsin (Promega), glycerol-free peptidyl-N-glycosidase F (PNGase F) (New England Biolabs), Endoglycosidase Hf (Endo Hf) (New England Biolabs), O-glycosidase (New England Biolabs), neuraminidase (New England Biolabs) and fetuin (New England Biolabs). All reagents and buffers were prepared with deionized water purified with a Millipore Direct-Q3 (Billerica, MA) water purification system.

Plasmids

The wild-type and mutant SARS-CoV-2 S glycoproteins were expressed transiently by a pcDNA3.1(-) vector (Thermo Fisher Scientific) (29). The wild-type SARS-CoV-2 spike (S) gene sequence, which encodes an aspartic acid residue at position 614, was obtained from the National Center for Biological Information (NC_045512.20). The gene was modified to encode a Gly₃ linker and His₆ tag at the carboxyl terminus. The modified S gene was codon-optimized, synthesized by Integrated DNA Technologies, and cloned into the pcDNA3.1(-) vector. S mutants were made using Q5 High-Fidelity 2X Master Mix and KLD Enzyme Mix for site-directed mutagenesis, according to the

manufacturer's protocol (New England Biolabs), and One-Shot TOP10 Competent Cells.

Inducible expression of the wild-type SARS-CoV-2 S glycoprotein was achieved using a self-inactivating lentivirus vector comprising TRE.3g-SARS-CoV-2-Spike.6His.IRES6A.Puro.T2A.GFP (K5650) (29). Here, the codon-optimized S gene is under the control of a tetracycline response element (TRE) promoter and encodes the wild-type S glycoprotein with a carboxy-terminal 2xStrep tag. The internal ribosome entry site (IRES6A) allows expression of puro.T2A.EGFP, in which puromycin N-acetyltransferase and enhanced green fluorescent protein (eGFP) are produced by self-cleavage at the Thosa assigna 2A (T2A) sequence.

Cell lines

The wild-type SARS-CoV-2 S glycoprotein, with Asp 614, was inducibly expressed in Lenti-x-293T human female kidney cells from Takara Bio (Catalog #: 632180). Lenti-x-293T cells were grown in DMEM with 10% FBS supplemented with L-glutamine and Pen-Strep.

Lenti-x-293T cells constitutively expressing the reverse tetracycline-responsive transcriptional activator (rtTA) (Lenti-x-293T-rtTa cells (D1317)) (29) were used as the parental cells for the 293T-S cell line. The 293T-S (D1483) cells inducibly expressing the wild-type SARS-CoV-2 S glycoprotein with a carboxy-terminal 2xStrep-Tag II sequence (29) were produced by transduction of Lenti-x-293T-rtTA cells with the K5650

recombinant lentivirus vector described above. The packaged K5650 lentivirus vector (60 µl volume) was incubated with 2x10⁵ Lenti-x-293T-rtTA cells in DMEM, tumbling at 37°C overnight. The cells were then transferred to a 6-well plate in 3 ml DMEM/10% FBS/Pen-Strep and subsequently selected with 10 µg/ml puromycin.

The GALE/GALK2 cells were obtained from Kerafast (73).

Expression and processing of S glycoprotein variants

293T cells were transfected with plasmids expressing the wild-type and mutant SARS-CoV-2 S glycoproteins. On the day prior to transfection, 293T cells were seeded in 6-well plates at a density of 1 x 10⁶/well. Cells were transfected with 1 microgram of S-expressing plasmid, using Lipofectamine 3000 according to the manufacturer's instructions. Two days after transfection, cells were lysed with lysis buffer (1x PBS, 1% NP-40 and 1x protease inhibitor cocktail) and the cell lysates analyzed by Western blotting. Samples were Western blotted with 1:2,000 dilutions of rabbit anti-SARS-Spike S1, mouse anti-SARS-Spike S1, rabbit anti-SARS-Spike S2 or a 1:5,000 dilution of mouse anti-β-actin as the primary antibodies. HRP-conjugated anti-rabbit or anti-mouse antibodies at a dilution of 1:5,000 were used as secondary antibodies in the Western blots. The adjusted integrated volumes of S, S1 and S2 bands from unsaturated Western blots were calculated using Fiji ImageJ. The values for the processing of mutant S glycoproteins were calculated and normalized to the values for the wild-type S glycoprotein (WT) as follows:

$$\text{Processing level} = (S1/S \times S2/S)_{\text{mutant}} \div (S1/S \times S2/S)_{\text{WT}}$$

For production of VLPs, the SARS-CoV-2 S glycoprotein was coexpressed with M, E and N proteins, individually or in combination. One day before transfection, 293T cells were seeded into 10-cm dishes at a density of 5.5×10^6 /dish. The next day, the cells were transfected with 3 micrograms of each expressor plasmid or with an empty vector plasmid to keep the total amount of DNA transfected at 12 micrograms. Two days after transfection, cell lysates were prepared as described above. Cell supernatants were cleared at 900 x g for 15 minutes, followed by centrifugation at 100,000 x g for one hour at 4°C. Pellets were washed with 800 µl of 1x PBS and then resuspended in 90 µl lysis buffer for 5 minutes on ice. In some cases, cell lysates and pellets prepared from cell supernatants were treated with PNGase F, Endoglycosidase Hf (Endo Hf), or O-glycosidase + neuraminidase (New England Biolabs), according to the manufacturer's instructions. Samples were analyzed by Western blotting as described above.

S1 shedding from S glycoprotein-expressing cells

293T cells were transfected with pcDNA3.1(-) plasmids expressing the wild-type and mutant SARS-CoV-2 S glycoproteins, using Lipofectamine 3000 according to the manufacturer's protocol. Cell supernatants were collected, cleared by centrifugation at 1800 x g for 10 minutes and incubated with a 1:100 dilution of NYP01 convalescent serum and Protein A-agarose beads for 1-2 hours at room temperature. Beads were washed three times and samples were Western blotted with a mouse anti-S1 antibody. Band intensity was determined as described above. The subunit association index of each mutant was calculated as follows:

$$\text{Subunit association} = \left(\frac{\text{lysate S1}}{\text{shed S1}} \right)_{\text{mutant}} \div \left(\frac{\text{lysate S1}}{\text{shed S1}} \right)_{\text{WT}}$$

Purification of the S glycoproteins

To express the SARS-CoV-2 S glycoprotein for purification, 293T-S cells were induced with 1 µg/ml doxycycline for two days. The cells were resuspended in 1x PBS and spun at 4500 x g for 15 minutes at 4°C. Cell pellets were collected and lysed by incubating in lysis buffer (20 mM Tris HCl (pH 8.0), 150 mM NaCl, 1% Cymal-5, 1x protease inhibitor cocktail (Roche)) on ice for 10 minutes. Cell lysates were spun at 10,000 x g for 20 minutes at 4°C, and the supernatant was incubated with Strep-Tactin XT Superflow resin (IBA # 2-4030-010) by rocking end over end at room temperature for 1.5 hours in a 50-ml conical tube. After incubation, the supernatant-resin suspension was applied to a Biorad column allowing flowthrough by gravity, followed by washing with 20 bed volumes of washing buffer (IBA # 2-1003-100 containing 0.5% Cymal-5), and elution with 10 bed volumes of elution buffer (IBA # 2-1042-025 containing 0.5% Cymal-5 and 1x protease inhibitor cocktail). For the second step of purification, the eluate was incubated with AAL-agarose resin (Vector Laboratories # AL-1393-2) at room temperature for 1 hour in a 10-ml conical tube. The eluate-AAL resin suspension was applied to a Biorad eco-column for gravity flowthrough. The column was washed with 20 bed volumes of washing buffer (20 mM Tris HCl (pH 8.0), 150 mM NaCl, 0.5% Cymal-5, 1x protease inhibitor cocktail (Roche)), after which the sample was eluted with 10 bed volumes of elution buffer (9 parts elution buffer (Vector Laboratories # ES-3100-100), 0.5 parts 1 M Tris HCl (pH 8.0), 0.5 parts 10% Cymal-5). The eluate was buffer exchanged by ultrafiltration three times to remove fucose; this was accomplished using

a 15-ml ultrafiltration tube (Thermo Fisher Scientific # UFC903024) at 4000 x g at room temperature with a buffer consisting of 20 mM Tris HCl (pH 8.0), 150 mM NaCl and 0.5% Cymal-5.

Proteolytic digestion of SARS-CoV-2 spike glycoproteins for glycosylation analysis

The purified SARS-CoV-2 S glycoprotein samples (30 µg) at a concentration of ~0.03 mg/mL were denatured with 7 M urea in 100 mM Tris buffer (pH 8.5), reduced at room temperature for one hour with TCEP (5 mM), and alkylated with 20 mM IAM at room temperature for another hour in the dark. The reduced and alkylated samples were buffer exchanged with 50 mM ammonium bicarbonate (pH 8) using a 50-kDa MWCO filter (Millipore) prior to trypsin digestion. The resulting buffer-exchanged sample was aliquoted into two portions – one digested with trypsin and the other with chymotrypsin. All protease digestions were performed according to manufacturer's suggested protocols: digestion with trypsin was performed with a 30:1 protein:enzyme ratio at 37°C for 18 hours; chymotrypsin digestion was performed with a 20:1 protein:enzyme ratio at 30°C for 10 hours; the combination of both proteases (a mixture of trypsin and chymotrypsin) was performed using the same protein:enzyme ratio as that used for single enzyme digestion and was incubated overnight at 37°C. Ten microliter aliquots from each digest were treated with PNGase F and incubated at 37°C. The digests were either directly analyzed or stored at -20°C until further analysis.

Disulfide bond analysis of SARS-CoV-2 spike glycoprotein

The disulfide bond profiles of the SARS-CoV-2 spike glycoproteins were determined as described previously (87, 88). Briefly, a sample containing 10 µg of the spike glycoprotein was buffer exchanged with 50 mM ammonium citrate buffer (pH 6.5) using a 50-kDa MWCO filter (Millipore). The resulting buffer-exchanged sample was alkylated with a 20-fold molar excess of 4-vinylpyridine in the dark for one hour at room temperature to cap free cysteine residues. The alkylated sample was subsequently deglycosylated with 500 U of PNGase F for one week at 37°C. The deglycosylated and alkylated sample was digested overnight with trypsin (protein to enzyme ratio of 30:1 at 37°C. A 20-µL aliquot from the tryptic digest was further treated with 1 µg chymotrypsin and was incubated for eight hours at 37°C. The digests were either directly analyzed or stored at -20°C until further analysis.

Chromatography and mass spectrometry

High-resolution LC/MS experiments were performed using an Orbitrap Fusion Lumos Tribrid (Thermo Scientific) mass spectrometer equipped with ETD that is coupled to an Acquity UPLC M-Class system (Waters). Mobile phases consisted of solvent A: 99.9% deionized H₂O + 0.1% formic acid and solvent B: 99.9 % CH₃CN + 0.1% formic acid. Three microliters of the sample was injected onto a C18 PepMap™ 300 column (300 µm i.d. x 15 cm, 300 Å, Thermo Fisher Scientific) at a flow rate of 3 µL/min. The following CH₃CN/H₂O multistep gradient was used: 3% B for 3 min, followed by a linear increase to 45% B in 50 min then a linear increase to 90% B in 15 min. The column was held at 90% B for 10 minutes before re-equilibration. All mass spectrometric analysis was performed in the positive ion mode using data-dependent acquisition with

the instrument set to run in 3-sec cycles for the survey and two consecutive MS/MS scans with CID and EThcD or ETciD. The full MS survey scans were acquired in the Orbitrap in the mass range 400-1800 m/z at a resolution of 120000 at m/z 200 with an AGC target of 4×10^5 . Following a survey scan, MS/MS scans were performed on the most intense ions with charge states ranging from 2-6 and with intensity greater than 5000. CID was carried out at with a collision energy of 30% while ETD was performed using the calibrated charge-dependent reaction time. Resulting fragments were detected using rapid scan rate in the ion trap.

Glycopeptide identification and disulfide bond analysis

Glycopeptide compositional analysis was performed as described previously (89,90). Briefly, compositional analysis of glycopeptides was carried out by first identifying the peptide portion from tandem MS data. Once the peptide portion was determined, plausible glycopeptide compositions were obtained using the high-resolution MS data and GlycoPep DB (91). The putative glycopeptide composition was confirmed manually from CID and ETD data.

Disulfide bond patterns of SARS CoV-2 spike glycoproteins were determined by mapping the disulfide-linked peptides. Data analysis was performed using the Mascot (v2.5.1) search engine (92) for peptides containing free cysteine residues, and disulfide bond patterns were analyzed manually, as described previously (87,88).

VSV pseudotyped by S glycoproteins

VSV was pseudotyped with S glycoproteins expressed stably in 293T-S cells or transiently in 293T cells. 293T-S cells in 6-well plates were induced with 1 µg/ml doxycycline or, as a control, incubated in standard medium without doxycycline. For transient expression, subconfluent 293T cells in a T75 flask were transfected with 15 µg of the SARS-CoV-2 S expressor plasmid using 60 µl of 1 mg/ml polyethylenimine (PEI). Twenty-four hours later, cells were infected at a multiplicity of infection of 3-5 for 2 hours at 37°C with rVSV-ΔG pseudovirus complemented in *trans* with the G glycoprotein and bearing a luciferase gene (Kerafast). Cells were then washed 6 times with DMEM + 10% FBS and returned to culture. Cell supernatants containing S-pseudotyped VSV were harvested 24 hours later, clarified by low-speed centrifugation (900 x g for 10 min), and either characterized immediately or stored at -80°C for later analysis.

Syncytium formation assay

293T-S cells in 6-well plates were cotransfected with 1 µg each of an eGFP-expressing plasmid and a plasmid expressing hACE2, and then incubated in either standard (control) medium or medium containing 1 µg/ml doxycycline. Twenty-four hours after transfection, cells were imaged using a fluorescence microscope with a green light filter. In parallel, cell lysates were collected for Western blotting, as described above.

Virus infectivity

VSV-ΔG vectors pseudotyped with SARS-CoV-2 S gp variants were produced as described above. The recombinant viruses were incubated with 293T-ACE2 cells, and 24 hours later, luciferase activity in the cells was measured.

Virus neutralization by sACE2 and sera

Neutralization assays were performed by adding 200-300 TCID₅₀ of rVSV-ΔG pseudotyped with SARS-CoV-2 S glycoprotein variants into serial dilutions of sACE2 and sera. The mixture was dispensed onto a 96-well plate in triplicate and incubated for 1 h at 37°C. Approximately 4 x 10⁴ 293T-ACE2 cells were then added to each well, and the cultures were maintained for an additional 24 h at 37°C before luciferase activity was measured. Neutralization activity was calculated from the reduction in luciferase activity compared to controls, using GraphPad Prism 8 (GraphPad Software Inc.).

DATA AVAILABILITY

All the data supporting the conclusions are contained in the manuscript.

ACKNOWLEDGMENTS

We thank Ms. Elizabeth Carpelan for preparation of the manuscript. We thank Lihong Liu and David Ho (Columbia University), Peihui Wang (Shandong University) and Yuan Liu (Cornell University) for reagents.

FUNDING AND ADDITIONAL INFORMATION

This study was supported by the University of Alabama at Birmingham Center for AIDS Research (NIH P30 AI27767), by grants from the National Institutes of Health

(AI125093 to H.D., J.C.K. and J.S. and R35 GM130354 to H.D.), and by a gift to J.S.

from the late William F. McCarty-Cooper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

REFERENCES

1. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, T. T. Y., Wu, J. T., Gao, G. F., Cowling, B. J., Yang, B., Leung, G. M., and Feng, Z. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* **382**, 1199-1207
2. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., and Cao, B. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497-506
3. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., and Zhang, Y. Z. (2020) A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265-269
4. Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., Zhao, K., Chen, Q. J., Deng, F., Liu, L. L., Yan, B., Zhan, F. X., Wang, Y. Y., Xiao, G. F., and Shi, Z. L. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273
5. Coronaviridae Study Group of the International Committee on Taxonomy of, V. (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-544
6. Lv, M., Luo, X., Estill, J., Liu, Y., Ren, M., Wang, J., Wang, Q., Zhao, S., Wang, X., Yang, S., Feng, X., Li, W., Liu, E., Zhang, X., Wang, L., Zhou, Q., Meng, W., Qi, X., Xun, Y., Yu, X., Chen, Y., On Behalf Of The, C.-E., and Recommendations Working, G. (2020) Coronavirus disease (COVID-19): a scoping review. *Euro Surveill* **25**. doi: 10.2807/1560-7917.ES.2020.25.15.2000125
7. Dowd, J. B., Andriano, L., Brazel, D. M., Rotondi, V., Block, P., Ding, X., Liu, Y., and Mills, M. C. (2020) Demographic science aids in understanding the spread and fatality rates of COVID-19. *Proc Natl Acad Sci U S A* **117**, 9696-9698
8. Tortorici, M. A., and Veasler, D. (2019) Structural insights into coronavirus entry. *Adv Virus Res* **105**, 93-116
9. Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., Xiang, Z., Mu, Z., Chen, X., Chen, J., Hu, K., Jin, Q., Wang, J., and Qian, Z. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* **11**, 1620
10. Li, F. (2016) Structure, function, and evolution of coronavirus spike proteins. *Annu Rev Virol* **3**, 237-261
11. Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veasler, D. (2020)

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181**, 281-292 e286

12. Yuan, M., Wu, N. C., Zhu, X., Lee, C. D., So, R. T. Y., Lv, H., Mok, C. K. P., and Wilson, I. A. (2020) A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* **368**, 630-633

13. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., and McLellan, J. S. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263

14. Venkat Kumar, G., Jeyanthi, V., and Ramakrishnan, S. (2020) A short review on antibody therapy for COVID-19. *New Microbes New Infect* **35**, 100682

15. Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., and Bosch, B. J. (2020) A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun* **11**, 2251

16. Callaway, E. (2020) The race for coronavirus vaccines: a graphical guide. *Nature* **580**, 576-577

17. Billington, J., Deschamps, I., Erck, S. C., Gerberding, J. L., Hanon, E., Ivol, S., Shiver, J. W., Spencer, J. A., and Van Hoof, J. (2020) Developing vaccines for SARS-CoV-2 and future epidemics and pandemics: Applying lessons from past outbreaks. *Health Secur* **18**, 241-249

18. Padron-Regalado, E. (2020) Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. *Infect Dis Ther*, 1-20. doi: 10.1007/s40121-020-00300-x

19. Venkat Kumar, G., Jeyanthi, V., and Ramakrishnan, S. (2020) A short review on antibody therapy for COVID-19. *New Microbes New Infect* **35**, 100682

20. Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., and Bosch, B. J. (2020) A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun* **11**, 2251

21. [preprint] Quinlan BD, Mou H, Zhang L, Guo YU, He W, Ojha A, Parcels MS, Luo G, Li W, Zhong G, Choe H, Farzan M. (2020) The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. *bioRxiv* doi: 10.1101/2020.04.10.036418

22. Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H. H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Jr., Rice, C. M., Hatzioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M., and Nussenzweig, M. C. (2020) Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437-442

23. Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W. T., Limbo, O., Smith, C., Song, G., Woehl, J., Yang, L., Abbott, R. K., Callaghan, S., Garcia, E., Hurtado, J., Parren, M.,

Peng, L., Ramirez, S., Ricketts, J., Ricciardi, M. J., Rawlings, S. A., Wu, N. C., Yuan, M., Smith, D. M., Nemazee, D., Teijaro, J. R., Voss, J. E., Wilson, I. A., Andrabi, R., Briney, B., Landais, E., Sok, D., Jardine, J. G., and Burton, D. R. (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956-963

24. Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., Tse, L. V., Johnson, N. V., Hsieh, C. L., Wang, N., Nett, J. H., Champney, E., Burnina, I., Brown, M., Lin, S., Sinclair, M., Johnson, C., Pudi, S., Bortz, R., 3rd, Wirchnianski, A. S., Laudermitch, E., Florez, C., Fels, J. M., O'Brien, C. M., Graham, B. S., Nemazee, D., Burton, D. R., Baric, R. S., Voss, J. E., Chandran, K., Dye, J. M., McLellan, J. S., and Walker, L. M. (2020) Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science* **369**, 731-736

25. Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schafer, A., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Martinez, D. R., Williamson, L. E., Chen, E. C., Jones, T., Day, S., Myers, L., Hassan, A. O., Kafai, N. M., Winkler, E. S., Fox, J. M., Shrihari, S., Mueller, B. K., Meiler, J., Chandrashekar, A., Mercado, N. B., Steinhardt, J. J., Ren, K., Loo, Y. M., Kallewaard, N. L., McCune, B. T., Keeler, S. P., Holtzman, M. J., Barouch, D. H., Gralinski, L. E., Baric, R. S., Thackray, L. B., Diamond, M. S., Carnahan, R. H., and Crowe, J. E., Jr. (2020) Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443-449

26. Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F., Sahi, V., Figueroa, A., Guo, X. V., Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Chen, Z., Yuen, K. Y., Kwong, P. D., Sodroski, J. G., Yin, M. T., Sheng, Z., Huang, Y., Shapiro, L., and Ho, D. D. (2020) Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450-456

27. Klasse, P. J., and Moore, J. P. (2020) Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. *Elife* **9**. doi: 10.7554/eLife.57877

28. Santopolo, S., Riccio, A., and Santoro, M. G. (2020) The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. *Biochem Biophys Res Commun*. doi: 10.1016/j.bbrc.2020.10.080

29. Nguyen, H. T., Zhang, S., Wang, Q., Anang, S., Wang, J., Ding, H., Kappes, J. C., and Sodroski, J. (2020) Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects. *J Virol*. doi: 10.1128/JVI.02304-20

30. Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., and Crispin, M. (2020) Site-specific glycan analysis of the SARS-CoV-2 spike. *Science* **369**, 330-333

31. Walls, A. C., Tortorici, M. A., Frenz, B., Snijder, J., Li, W., Rey, F. A., DiMaio, F., Bosch, B. J., and Veisler, D. (2016) Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. *Nat Struct Mol Biol* **23**, 899-905

32. Xiong, X., Tortorici, M. A., Snijder, J., Yoshioka, C., Walls, A. C., Li, W., McGuire, A. T., Rey, F. A., Bosch, B. J., and Veisler, D. (2018) Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections. *J Virol* **92**. doi: 10.1128/JVI.01628-17

33. Zhao, P., Praissman, J. L., Grant, O. C., Cai, Y., Xiao, T., Rosenbalm, K. E., Aoki, K., Kellman, B. P., Bridger, R., Barouch, D. H., Brindley, M. A., Lewis, N. E., Tiemeyer, M., Chen, B., Woods, R. J., and Wells, L. (2020) Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. *Cell Host Microbe* **28**, 586-601 e586
34. Wang, D., Baudys, J., Bundy, J. L., Solano, M., Keppel, T., and Barr, J. R. (2020) Comprehensive analysis of the glycan complement of SARS-CoV-2 spike proteins using signature ions-triggered electron-transfer/higher-energy collisional dissociation (ETHcD) mass spectrometry. *Anal Chem* **92**, 14730-14739
35. Shajahan, A., Supekar, N. T., Gleinich, A. S., and Azadi, P. (2020) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. *Glycobiology* **30**, 981-988
36. [preprint] Sanda, M., Morrison, L., and Goldman, R. (2020) N and O glycosylation of the SARS-CoV-2 spike protein. *bioRxiv* doi: 10.1101/2020.07.05.187344
37. Lontok, E., Corse, E., and Machamer, C. E. (2004) Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site. *J Virol* **78**, 5913-5922
38. McBride, C. E., Li, J., and Machamer, C. E. (2007) The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. *J Virol* **81**, 2418-2428
39. Stertz, S., Reichelt, M., Spiegel, M., Kuri, T., Martinez-Sobrido, L., Garcia-Sastre, A., Weber, F., and Kochs, G. (2007) The intracellular sites of early replication and budding of SARS-coronavirus. *Virology* **361**, 304-315
40. Ujike, M., Huang, C., Shirato, K., Makino, S., and Taguchi, F. (2016) The contribution of the cytoplasmic retrieval signal of severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and incorporation of S protein into virus-like particles. *J Gen Virol* **97**, 1853-1864
41. Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., and Li, F. (2020) Structural basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221-224
42. Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **367**, 1444-1448
43. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., and Pohlmann, S. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181**, 271-280 e278
44. Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., and Lu, L. (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res* **30**, 343-355
45. Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., and Decroly, E. (2020) The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage

site absent in CoV of the same clade. *Antiviral Res* **176**, 104742

46. Hoffmann, M., Kleine-Weber, H., and Pohlmann, S. (2020) A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. *Mol Cell* **78**, 779-784 e775
47. Belouzard, S., Chu, V. C., and Whittaker, G. R. (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci U S A* **106**, 5871-5876
48. Walls, A. C., Xiong, X., Park, Y. J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., Zambon, M., Rey, F. A., Corti, D., and Vesler, D. (2019) Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. *Cell* **176**, 1026-1039 e1015
49. Rossen, J. W., de Beer, R., Godeke, G. J., Raamsman, M. J., Horzinek, M. C., Vennema, H., and Rottier, P. J. (1998) The viral spike protein is not involved in the polarized sorting of coronaviruses in epithelial cells. *J Virol* **72**, 497-503
50. Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., Peter, A., Guarino, B., Spreafico, R., Cameroni, E., Case, J. B., Chen, R. E., Havenar-Daughton, C., Snell, G., Telenti, A., Virgin, H. W., Lanzavecchia, A., Diamond, M. S., Fink, K., Vesler, D., and Corti, D. (2020) Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290-295
51. Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J. H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., 3rd, Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., and Ward, A. B. (2020) Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science* **370**, 1089-1094
52. Yao, H., Song, Y., Chen, Y., Wu, N., Xu, J., Sun, C., Zhang, J., Weng, T., Zhang, Z., Wu, Z., Cheng, L., Shi, D., Lu, X., Lei, J., Crispin, M., Shi, Y., Li, L., and Li, S. (2020) Molecular architecture of the SARS-CoV-2 virus. *Cell* **183**, 730-738 e713
53. [preprint] Brun J, Vasiljevic S, Gangadharan B, Hensen M, Chandran AV, Hill ML, Kiappes JL, Dwek RA, Alonzi DS, Struwe WB, Zitzmann N. (2020) Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidate. *bioRxiv* doi: 10.1101/2020.11.16.384594
54. Go, E. P., Herschhorn, A., Gu, C., Castillo-Menendez, L., Zhang, S., Mao, Y., Chen, H., Ding, H., Wakefield, J. K., Hua, D., Liao, H. X., Kappes, J. C., Sodroski, J., and Desaire, H. (2015) Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. *J Virol* **89**, 8245-8257
55. Go, E. P., Ding, H., Zhang, S., Ringe, R. P., Nicely, N., Hua, D., Steinbock, R. T., Golabek, M., Alin, J., Alam, S. M., Cupo, A., Haynes, B. F., Kappes, J. C., Moore, J. P., Sodroski, J. G., and Desaire, H. (2017) Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers. *J Virol* **91**. doi: 10.1128/JVI.02428-16
56. Cao, L., Pauthner, M., Andrabi, R., Rantalainen, K., Berndsen, Z., Diedrich, J. K., Menis, S., Sok, D., Bastidas, R., Park, S. R., Delahunty, C. M., He, L., Guenaga, J., Wyatt, R. T., Schief,

- W. R., Ward, A. B., Yates, J. R., 3rd, Burton, D. R., and Paulson, J. C. (2018) Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. *Nat Commun* **9**, 3693
57. Torrents de la Pena, A., Rantalainen, K., Cottrell, C. A., Allen, J. D., van Gils, M. J., Torres, J. L., Crispin, M., Sanders, R. W., and Ward, A. B. (2019) Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. *PLoS Pathog* **15**, e1007920
58. Siu, Y. L., Teoh, K. T., Lo, J., Chan, C. M., Kien, F., Escriou, N., Tsao, S. W., Nicholls, J. M., Altmeyer, R., Peiris, J. S., Bruzzone, R., and Nal, B. (2008) The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. *J Virol* **82**, 11318-11330
59. Boson, B., Legros, V., Zhou, B., Siret, E., Mathieu, C., Cosset, F. L., Lavillette, D., and Denolly, S. (2020) The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the Spike protein, allowing assembly of virus-like particles. *J Biol Chem*, 100111. doi: 10.1074/jbc.RA120.016175
60. Long, A. R., O'Brien, C. C., Malhotra, K., Schwall, C. T., Albert, A. D., Watts, A., and Alder, N. N. (2013) A detergent-free strategy for the reconstitution of active enzyme complexes from native biological membranes into nanoscale discs. *BMC Biotechnol* **13**, 41
61. Knowles, T. J., Finka, R., Smith, C., Lin, Y. P., Dafforn, T., and Overduin, M. (2009) Membrane proteins solubilized intact in lipid containing nanoparticles bounded by styrene maleic acid copolymer. *J Am Chem Soc* **131**, 7484-7485
62. Jamshad, M., Grimard, V., Idini, I., Knowles, T. J., Dowle, M. R., Schofield, N., Sridhar, P., Lin, Y. P., Finka, R., Wheatley, M., Thomas, O. R., Palmer, R. E., Overduin, M., Govaerts, C., Ruysschaert, J. M., Edler, K. J., and Dafforn, T. R. (2015) Structural analysis of a nanoparticle containing a lipid bilayer used for detergent-free extraction of membrane proteins. *Nano Res* **8**, 774-789
63. Lee, S. C., Knowles, T. J., Postis, V. L., Jamshad, M., Parslow, R. A., Lin, Y. P., Goldman, A., Sridhar, P., Overduin, M., Muench, S. P., and Dafforn, T. R. (2016) A method for detergent-free isolation of membrane proteins in their local lipid environment. *Nat Protoc* **11**, 1149-1162
64. Orwick, M. C., Judge, P. J., Procek, J., Lindholm, L., Graziadei, A., Engel, A., Grobner, G., and Watts, A. (2012) Detergent-free formation and physicochemical characterization of nanosized lipid-polymer complexes: Lipodisq. *Angew Chem Int Ed Engl* **51**, 4653-4657
65. Morrison, K. A., Akram, A., Mathews, A., Khan, Z. A., Patel, J. H., Zhou, C., Hardy, D. J., Moore-Kelly, C., Patel, R., Odiba, V., Knowles, T. J., Javed, M. U., Chmel, N. P., Dafforn, T. R., and Rothnie, A. J. (2016) Membrane protein extraction and purification using styrene-maleic acid (SMA) copolymer: effect of variations in polymer structure. *Biochem J* **473**, 4349-4360
66. Wu, D., Li, J., Struwe, W. B., and Robinson, C. V. (2019) Probing N-glycoprotein microheterogeneity by lectin affinity purification-mass spectrometry analysis. *Chem Sci* **10**, 5146-5155
67. Johansen, E., Schilling, B., Lerch, M., Niles, R. K., Liu, H., Li, B., Allen, S., Hall, S. C.,

- Witkowska, H. E., Regnier, F. E., Gibson, B. W., Fisher, S. J., and Drake, P. M. (2009) A lectin HPLC method to enrich selectively-glycosylated peptides from complex biological samples. *J Vis Exp*. doi: 10.3791/1398
68. Iskratsch, T., Braun, A., Paschinger, K., and Wilson, I. B. (2009) Specificity analysis of lectins and antibodies using remodeled glycoproteins. *Anal Biochem* **386**, 133-146
69. Stanley, P. (2011) Golgi glycosylation. *Cold Spring Harb Perspect Biol* **3**. doi: 10.1101/cshperspect.a005199
70. Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Jr., Rawson, S., Rits-Volloch, S., and Chen, B. (2020) Distinct conformational states of SARS-CoV-2 spike protein. *Science* **369**, 1586-1592
71. Zhu, Z., and Desaire, H. (2015) Carbohydrates on proteins: Site-specific glycosylation analysis by mass spectrometry. *Annu Rev Anal Chem (Palo Alto Calif)* **8**, 463-483
72. Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Wang, S., Zhong, Y., Su, T., Gong, M., Du, D., Lu, X., Cheng, J., and Yang, H. (2020) Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 Spike Proteins. *Mol Cell Proteomics*. doi: 10.1074/mcp.RA120.002295
73. Termini, J. M., Silver, Z. A., Connor, B., Antonopoulos, A., Haslam, S. M., Dell, A., and Desrosiers, R. C. (2017) HEK293T cell lines defective for O-linked glycosylation. *PLoS One* **12**, e0179949
74. Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., Hastie, K. M., Parker, M. D., Partridge, D. G., Evans, C. M., Freeman, T. M., de Silva, T. I., Sheffield, C.-G. G., McDanal, C., Perez, L. G., Tang, H., Moon-Walker, A., Whelan, S. P., LaBranche, C. C., Saphire, E. O., and Montefiori, D. C. (2020) Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **182**, 812-827 e819
75. [preprint] Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Rangarajan, E. S., Izard, T., Farzan, M., and Choe, H. (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* doi: 10.1101/2020.06.12.148726. Update in: *Nat Commun* **11**,6013
76. Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J. B., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., Dudkina, N. V., Shen, K., and Luban, J. (2020) Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* **183**, 739-751 e738
77. Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. *Glob Chall* **1**, 33-46
78. Shu, Y., and McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill* **22**. doi: 10.2807/1560-7917.ES.2017.22.13.30494
79. Zhang, X. Y., Guo, J., Wan, X., Zhou, J. G., Jin, W. P., Lu, J., Wang, W. H., Yang, A. N., Liu, D. X., Shi, Z. L., Yuan, Z. M., Li, X. G., Meng, S. L., Duan, K., Wang, Z. J., Yang, X. M., and

Shen, S. (2020) Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate. *Emerg Microbes Infect* **9**, 2653-2662

80. Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schafer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., Hutchinson, G. B., Wu, K., Henry, C., Bahl, K., Garcia-Dominguez, D., Ma, L., Renzi, I., Kong, W. P., Schmidt, S. D., Wang, L., Zhang, Y., Phung, E., Chang, L. A., Loomis, R. J., Altaras, N. E., Narayanan, E., Metkar, M., Presnyak, V., Liu, C., Louder, M. K., Shi, W., Leung, K., Yang, E. S., West, A., Gully, K. L., Stevens, L. J., Wang, N., Wrapp, D., Doria-Rose, N. A., Stewart-Jones, G., Bennett, H., Alvarado, G. S., Nason, M. C., Ruckwardt, T. J., McLellan, J. S., Denison, M. R., Chappell, J. D., Moore, I. N., Morabito, K. M., Mascola, J. R., Baric, R. S., Carfi, A., and Graham, B. S. (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature* **586**, 567-571

81. Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., Martinez, D. R., Loos, C., Atyeo, C., Fischinger, S., Burke, J. S., Slein, M. D., Chen, Y., Zuiani, A., Lelis, F. J. N., Travers, M., Habibi, S., Pessaint, L., Van Ry, A., Blade, K., Brown, R., Cook, A., Finneyfrock, B., Dodson, A., Teow, E., Velasco, J., Zahn, R., Wegmann, F., Bondzie, E. A., Dagotto, G., Gebre, M. S., He, X., Jacob-Dolan, C., Kirilova, M., Kordana, N., Lin, Z., Maxfield, L. F., Nampanya, F., Nityanandam, R., Ventura, J. D., Wan, H., Cai, Y., Chen, B., Schmidt, A. G., Wesemann, D. R., Baric, R. S., Alter, G., Andersen, H., Lewis, M. G., and Barouch, D. H. (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* **369**, 806-811

82. Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O'Connell, S., Bock, K. W., Minai, M., Nagata, B. M., Andersen, H., Martinez, D. R., Noe, A. T., Douek, N., Donaldson, M. M., Nji, N. N., Alvarado, G. S., Edwards, D. K., Flebbe, D. R., Lamb, E., Doria-Rose, N. A., Lin, B. C., Louder, M. K., O'Dell, S., Schmidt, S. D., Phung, E., Chang, L. A., Yap, C., Todd, J. M., Pessaint, L., Van Ry, A., Browne, S., Greenhouse, J., Putman-Taylor, T., Strasbaugh, A., Campbell, T. A., Cook, A., Dodson, A., Steingrebe, K., Shi, W., Zhang, Y., Abiona, O. M., Wang, L., Pegu, A., Yang, E. S., Leung, K., Zhou, T., Teng, I. T., Widge, A., Gordon, I., Novik, L., Gillespie, R. A., Loomis, R. J., Moliva, J. I., Stewart-Jones, G., Himansu, S., Kong, W. P., Nason, M. C., Morabito, K. M., Ruckwardt, T. J., Ledgerwood, J. E., Gaudinski, M. R., Kwong, P. D., Mascola, J. R., Carfi, A., Lewis, M. G., Baric, R. S., McDermott, A., Moore, I. N., Sullivan, N. J., Roederer, M., Seder, R. A., and Graham, B. S. (2020) Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *N Engl J Med* **383**, 1544-1555

83. Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., He, X., Martinez, D. R., Rutten, L., Bos, R., van Manen, D., Vellinga, J., Custers, J., Langedijk, J. P., Kwaks, T., Bakkers, M. J. G., Zuijdgheest, D., Rosendahl Huber, S. K., Atyeo, C., Fischinger, S., Burke, J. S., Feldman, J., Hauser, B. M., Caradonna, T. M., Bondzie, E. A., Dagotto, G., Gebre, M. S., Hoffman, E., Jacob-Dolan, C., Kirilova, M., Li, Z., Lin, Z., Mahrokhian, S. H., Maxfield, L. F., Nampanya, F., Nityanandam, R., Nkolola, J. P., Patel, S., Ventura, J. D., Verrington, K., Wan, H., Pessaint, L., Van Ry, A., Blade, K., Strasbaugh, A., Cabus, M., Brown, R., Cook, A., Zouantchangadou, S., Teow, E., Andersen, H., Lewis, M. G., Cai, Y., Chen, B., Schmidt, A. G., Reeves, R. K., Baric, R. S., Lauffenburger, D. A., Alter, G., Stoffels, P., Mammen, M., Van Hoof, J., Schuitemaker, H., and Barouch, D. H. (2020) Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature* **586**, 583-588

84. Bos, R., Rutten, L., van der Lubbe, J. E. M., Bakkers, M. J. G., Hardenberg, G., Wegmann, F., Zuijdgheest, D., de Wilde, A. H., Koornneef, A., Verwilligen, A., van Manen, D., Kwaks, T., Vogels, R., Dalebout, T. J., Myeni, S. K., Kikkert, M., Snijder, E. J., Li, Z., Barouch, D. H., Vellinga, J., Langedijk, J. P. M., Zahn, R. C., Custers, J., and Schuitemaker, H. (2020) Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. *NPJ Vaccines* **5**, 91
85. Casalino, L., Gaieb, Z., Goldsmith, J. A., Hjorth, C. K., Dommer, A. C., Harbison, A. M., Fogarty, C. A., Barros, E. P., Taylor, B. C., McLellan, J. S., Fadda, E., and Amaro, R. E. (2020) Beyond shielding: The roles of glycans in the SARS-CoV-2 spike protein. *ACS Cent Sci* **6**, 1722-1734
86. Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Zhang, L., Li, X., Huang, W., and Wang, Y. (2020) The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. *Cell* **182**, 1284-1294 e1289
87. Go, E. P., Zhang, Y., Menon, S., and Desaire, H. (2011) Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 DeltaCFI shows variability in the V1 and V2 regions. *J Proteome Res* **10**, 578-591
88. Go, E. P., Hua, D., and Desaire, H. (2014) Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. *J Proteome Res* **13**, 4012-4027
89. Go, E. P., Irungu, J., Zhang, Y., Dalpathado, D. S., Liao, H. X., Sutherland, L. L., Alam, S. M., Haynes, B. F., and Desaire, H. (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. *J Proteome Res* **7**, 1660-1674
90. Irungu, J., Go, E. P., Zhang, Y., Dalpathado, D. S., Liao, H. X., Haynes, B. F., and Desaire, H. (2008) Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. *J Am Soc Mass Spectrom* **19**, 1209-1220
91. Go, E. P., Rebecchi, K. R., Dalpathado, D. S., Bandu, M. L., Zhang, Y., and Desaire, H. (2007) GlycoPep DB: a tool for glycopeptide analysis using a "Smart Search". *Anal Chem* **79**, 1708-1713
92. Perkins, D. N., Pappin, D. J., Creasy, D. M., and Cottrell, J. S. (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. *Electrophoresis* **20**, 3551-3567

FIGURES

Figure 1. The effect of coexpression of SARS-CoV-2 M, E and N proteins on S

glycosylation. (A-C) 293T cells were transfected with plasmids expressing the indicated SARS-CoV-2 proteins (S – spike glycoprotein; M – membrane protein; E – envelope protein; N – nucleocapsid protein). Two days after transfection, cells were lysed and particles were prepared by centrifugation of cell supernatants. (A) Cell lysates and supernatant pellets (Sup) were Western blotted with anti-S1 (upper two panels) and anti-S2 (lower two panels) antibodies. (B) Supernatant pellets were treated with either PNGase F or Endo Hf and then Western blotted with anti-S1 or anti-S2 antibodies. Endo Hf-resistant and Endo Hf-sensitive forms of the S glycoprotein are indicated by S_r and S_s, respectively. (C) Cell lysates and supernatant pellets (Sup) were Western blotted with antibodies against the N, M and E proteins.

Figure 2. Inducible expression of a functional SARS-CoV-2 S glycoprotein. (A)

293T-S cells were transfected with plasmids expressing eGFP and human ACE2 (hACE2) and then incubated in medium with or without 1 µg/ml doxycycline (Doxy). Two days later, cells were imaged with a fluorescence microscope. Cell lysates were Western blotted with a mouse antibody against S1, a rabbit antibody against S2, a goat antibody against hACE2 and a mouse antibody against α-β-actin. (B) 293T-S cells were cultured for 24 hours in medium with 1 µg/ml doxycycline (Doxy) or in control medium. The cells were then infected with a G glycoprotein-pseudotyped VSVΔG virus encoding luciferase. One day later, virus particles were harvested from pre-cleared cell

supernatants and incubated with 293T-hACE2 cells. Luciferase activity was measured one day later. Cell lysates and viruses concentrated by a 100,000 x g centrifugation were Western blotted with a mouse antibody against S1, a rabbit antibody against S2, and an anti- α - β -actin antibody.

Figure 3. Purification of the SARS-CoV-2 S glycoproteins. (A) 293T-S cells induced with doxycycline for two days were lysed in buffers containing the indicated detergents or styrene-maleic acid (SMA) copolymers. The cell lysates were either directly Western blotted (Lysate) or used for S glycoprotein purification by Strep-Tactin XT at the indicated temperature. The purified S glycoproteins were Western blotted with rabbit antibodies against S1 (upper panel) and S2 (lower panel). (B) Purified S glycoproteins were analyzed on a Blue Native gel, which was stained with silver. (C) A lysate of 293T-S cells in a buffer containing Cymal-5 was purified by Strep-Tactin XT, followed by purification on Aleuria aurantia lectin (AAL)-agarose resin. The samples at various stages of purification were analyzed by SDS-PAGE and silver staining. FT – flow-through fraction. (D) The purified S glycoproteins were analyzed by SDS-PAGE and Coomassie Blue staining.

Figure 4. Disulfide bond topology of the purified S1 glycoproteins. MS analysis of the purified S1 glycoproteins identified 10 canonical disulfide bonds between the cysteine residues highlighted in red. Glycosylated asparagine residues converted to aspartic acid residues by PNGase F treatment are highlighted in blue.

Figure 5. Disulfide bond topology of the purified S glycoproteins. MS analysis of the purified S2 glycoproteins identified 5 canonical disulfide bonds (upper panel). The MS analysis also identified one alternative disulfide bond in the S1 glycoprotein (lower panel). Cysteine residues participating in the disulfide bonds are highlighted in red. The glycosylated asparagine residue converted to an aspartic acid residue by PNGase F treatment is highlighted in blue.

Figure 6. Glycosylation profile of the purified S glycoproteins. MS analysis of the purified S glycoproteins identified 22 N-linked glycosylation sites as well as O-linked glycosylation sites, summarized in the upper panel. The glycan composition at each N-linked glycosylation site is shown in the lower panel. Serine and threonine residues contained in glycopeptides with O-linked carbohydrates are indicated by arrows.

Figure 7. SARS-CoV-2 S glycopeptides. (A) The sequences of the S glycopeptides with N-linked glycosylation are shown, with the modified asparagine residues highlighted in red. The percentage of glycans that are high-mannose (HM), processed (Proc) (complex + hybrid), modified by fucose (Fuc) or sialylated (Sia) are indicated. (B) The sequences of S glycopeptides with O-linked glycosylation are shown, with the potentially modified serine and threonine residues highlighted in green. Asparagine residues in the glycopeptides that are modified by N-linked glycans are highlighted in red.

Figure 8. Glycan composition of different SARS-CoV-2 S glycoprotein

preparations. The glycan composition at each of the potential S glycoprotein N-linked glycosylation sites from this study (upper row) (*) is compared with those defined for SARS-CoV-2 S glycoproteins from various sources. Some of the S glycoproteins have been produced in soluble forms with alterations of the furin cleavage site (cl-) and with proline substitutions (2P or multiP) to stabilize pre-fusion conformations.

Figure 9. Location of glycans on the SARS-CoV-2 S glycoprotein trimer. N-linked glycans associated with the indicated asparagine residues are shown on the cryo-EM structure of a solubilized SARS-CoV-2 S glycoprotein trimer (PDB 6XR8) (70). The S1 subunits are colored light grey, and the S2 subunits are colored dark grey. The receptor-binding motif is colored cyan. The glycans are colored according to the level of processing observed in our study.

Figure 10. Characterization of wild-type and D614G S glycoproteins in GALE/GALK2 293T cells. (A) The wild-type SARS-CoV-2 S glycoprotein (D614, with an aspartic acid residue at 614) and the D614G variant (G614, with a glycine residue at 614) were expressed in wild-type 293T cells (wt) or in GALE/GALK2 293T cells (ko) (73). Cell lysates were untreated (No Rx) or were treated with the indicated glycosidase(s), followed by Western blotting with a mouse antibody against S1 (upper panels) or a rabbit antibody against S2 (lower panels). The S glycoproteins, either untreated or treated with different glycosidases, are indicated by red arrows. (B) As a control, fetuin, which has N- and O-linked glycans, was treated with the indicated glycosidases. The different fetuin glycoforms are indicated by red arrows.

Figure 11. Phenotypes of natural S glycoprotein variants. (A-C) The wild-type SARS-CoV-2 S glycoprotein and the indicated mutants were expressed in 293T cells. Cell lysates were prepared and, in some cases, treated with PNGase F, Endo Hf or PNGase F + O-glycosidase + neuraminidase. The cell lysates were Western blotted. In A, cell supernatants were also collected, precleared by centrifugation at 1800 x g for 10 minutes and used for precipitation by a 1:100 dilution of NYP01 convalescent serum and Protein A-agarose beads. The processing and subunit association indices shown in Table 1 were calculated for each mutant and were normalized to those of the wild-type (wt) S glycoprotein. In B and C, the effects of glycosidases on the wild-type and mutant S glycoproteins in cell lysates are shown. Endo Hf-resistant (S_r) and -sensitive (S_s) forms of the uncleaved S glycoprotein are indicated.

Figure 12. Neutralization of viruses pseudotyped with S glycoprotein variants. The sensitivity of VSV pseudotypes with the indicated S glycoproteins to neutralization by sACE2 or the NYP01, NYP21 and NYP22 convalescent-phase sera is shown. The infectivity is shown relative to that of a mock-treated virus.

Table 1. Glycosylation site occupancy.

The sequences of the SARS-CoV-2 glycopeptides with N-linked glycosylation (A) and O-linked glycosylation (B) are shown, with the potential sites of glycosylation highlighted in red and green, respectively. The occupancy at each potential N-linked glycosylation (PNG) or O-linked glycosylation site is indicated.

Table 2. Phenotypes of natural S glycoprotein variants.

The processing, subunit association and infectivity of the mutant S glycoproteins, relative to those of the wild-type S glycoprotein, are shown (–, undetectable; +, 1-10% of wild-type level; ++, 11-30% of wild-type level; +++, 31-80% of wild-type level; +++++, 81-120% of wild-type level; NA – not applicable). The location of the altered amino acid residue in the S glycoprotein is indicated: NTD – N-terminal domain; RBD – receptor-binding domain; CTD2 – C-terminal domain 2; HR2 – heptad repeat 2.

Figure 1.

Figure 2.

A.

B.

Figure 3.

Figure 4.

Disulfide-Linked Peptides	CS	Theoretical m/z	Experimental m/z	Mass Error (ppm)
Pyro-Q ^{C15} V ^{D17} L ^{C136} NDPF	2+	576.7205	576.7203	0.3
V ^{C131} EF SSAN ^{D165} ^{C166} TF	2+ 3+	669.7525 446.8374	669.7523 446.8371	0.3 1
YNED ^{D282} GTITDAVD ^{C292} ALDPLSETK ^{C301} TLK	2+ 3+ 4+	1416.1518 944.4370 708.5795	1416.1507 944.4364 708.5802	1 1 1
FP ^{D331} ITNL ^{C336} PFGEVFD ^{D343} ATR ISN ^{C361} VADYSVLYNSASFSTFK	3+ 4+ 5+	1452.3485 1089.5132 871.8120	1452.3494 1089.5133 871.8117	1 0.1 0.4
^{C379} YGVSPSTK LPDDFTG ^{C432} VIAWNSNNLDSK	2+ 3+ 4+	1530.7076 1020.8075 765.8574	1530.7064 1020.8071 765.8571	1 0.4 0.4
LNDL ^{C391} FTNVYADSFVIR VVVLSFELLHAPATV ^{C525} GPK	3+ 4+ 5+	1323.0214 992.5179 794.2158	1332.0214 992.5179 794.2166	0 0 1
DISTEIYQAGSTP ^{C480} NGVEGFN ^{C488} YFPLQSYG- FQPTNGVGYQPYPYR	3+ 4+ 5+	1589.3796 1192.2865 954.0306	1589.3718 1192.2851 954.0294	1 1 1
^{C538} VNF DITP ^{C590} SF	2+ 3+	631.2651 421.1791	631.2645 421.1786	1 1
QDVDC ^{C617} TEVPVAIH AG ^{C649} L	2+ 3+ 4+	893.4110 595.9431 447.2091	893.4107 595.9428 447.2090	0.3 0.4 0.3
EC ^{C662} DIPIGAGIC ^{C671} ASY	1+ 2+	1409.6077 705.3075	1409.6068 705.3066	1 1

Figure 5.

Canonical disulfide bonds in S2				
Disulfide-Linked Peptides	CS	Theoretical m/z	Experimental m/z	Mass Error (ppm)
TSVD ^{C738} TMYI ^{C743} GDSTE ^{C749} SNLLLQYGSF ^{C760} TQLNR	2+	1718.2587	1781.2590	0.2
	3+	1187.8415	1187.8420	0.4
	4+	891.1330	891.1333	0.4
QYGD ^{C840} LG DIAAR	2+	1034.9933	1034.9937	0.4
DLI ^{C851} AQK	3+	690.3313	690.3318	1
	4+	518.0002	518.0004	0.3
MSE ^{C1032} VLGQSK	2+	873.8967	873.8970	0.3
VDF ^{C1043} GK	3+	582.9336	582.9337	0.2
	4+	437.4520	437.4520	0
TTAPAI ^{C1082} HDGK	2+	1439.1915	1439.1914	0
VSGN ^{C1126} DVVIGIV ^{D1134} NTVY	3+	959.7967	959.7961	0.4
	4+	720.0994	720.0992	0.2
Alternative disulfide bond in S1				
Disulfide-Linked Peptides	CS	Theoretical m/z	Experimental m/z	Mass Error (ppm)
VC ^{C131} EFQFC ^{C136} NDPFLGVYYHK	2+	1103.9899	1103.9915	1
	3+	736.3290	736.3296	1
	4+	552.4986	552.4985	0.2

Figure 6.

Glycosylation Analysis of the SARS-CoV-2 S Glycoproteins

Summary:

Glycosylation	Number	Detected	No. of Glycans
N-linked	22	22	826*
O-linked	3 previously reported (T323,S325,T678)	10 detected (T323,S325,S659,S673,T676,T678,S680,T696,T1160,S1170)	17

* Total N-linked glycans used in the bar graph

Glycosylation

Figure 7.

A. N-Linked Sites: 22 sites

Glycosylated Peptides (N-Linked)	Count	%HM	% Proc	%Fuc	% Sia
Pyro_QCVN ¹⁷ LTTR	63	10	90	86	35
FSN ⁶¹ VTWF	28	18	82	48	0
HAIHVS ⁷⁴ GTK	27	22	78	91	33
TQSLIVN ¹²² ATNVVIV/IVN ¹²² ATNVVIV	47	11	89	60	29
HKN ¹⁴⁹ NKSWMESEF/N ¹⁴⁹ NK	18	11	89	81	50
VYSSAN ¹⁶⁵ CTFEYVSQPFLMDLEGK/SSANN ¹⁶⁵ CTF	29	17	83	54	25
DLPQGFSALEPLVDLP ^{IGIN} 234ITR/SALEPLVDLP ^{IGIN} 234ITR	42	17	83	60	20
YNE ²⁸² GTITDAVDCALDPLSETK	47	15	85	58	12
FPN ³³¹ ITNLCPF/FPN ³³¹ ITNL	36	6	94	79	35
GEVFN ³⁴³ ATRF/N ³⁴³ ATRF	20	25	75	73	0
GGVSVITPGTN ⁶⁰³ TSNQAVLY	30	20	80	67	4
QDVN ⁶¹⁶ CTEVPVAIHADQLTPTWR/QDVN ⁶¹⁶ CTEVPVAIHADQL	41	15	85	66	26
AGCLIGAEHV ⁶⁵⁷ NSYECDIPIGAGICASYQTQTN ^{SPR} /AGCLIGAEHV ⁶⁵⁷ NSY	20	10	90	100	39
SVASQSIAYTMSLGAENSVAYS ⁷⁰⁹ NSIAIPT ⁷¹⁷ FTISVTTEILPVSM ^{TK} /SN ⁷⁰⁹ NSIAIPT ⁷¹⁷ F	26	38	62	56	0
DFGGFN ⁸⁰¹ FSQILPDPSKPSK/TPPIKDFGGFN ⁸⁰¹ FSQILPDPSKPSK	67	8	92	53	37
GYHLSFSPQSAPHGVVFLHVTYVPAQEKN ¹⁰⁷⁴ FTTAPAICH ^{DGK} / N ¹⁰⁷⁴ FTTAPAICH ^{DGK} / VPAQEKN ¹⁰⁷⁴ F	92	6	94	62	36
EGVFVSN ¹⁰⁹⁸ GTHWFVTQR/VFVSN ¹⁰⁹⁸ GTHW	92	5	95	49	56
VSGNCDVVIGIVN ¹¹³⁴ NTVY	66	8	92	87	48
N ¹¹⁵⁸ HTSPDVLGD ^{ISGIN} 1173ASVVNIQK	5	0	100	100	80
NLN ¹¹⁹⁴ ESLIDLQELGK	30	7	93	93	75

B. O-Linked Sites: 10 sites

Glycosylated Peptides (O-Linked)	Number of Glycans
VQPT ³²³ ES ³²⁵ IVR	4
AGCLIGAEHV ⁶⁵⁷ NS ⁶⁵⁹ YECDIPIGAGICAS ⁶⁷³ YQT ⁶⁷⁶ Q T ⁶⁷⁸ NS ⁶⁸⁰ PR	9
T ⁶⁹⁶ MSLGAENSVAY	1
N ¹¹⁵⁸ HT ¹¹⁶⁰ SPDVLGD ^{ISGIN} 1173ASVVNIQK	3

Figure 9.

Figure 10.

A.

B.

PNGase F: - - + + + +
 O-Glycosidase: - - - - + +
 Neuraminidase: - - - - + +

Figure 12.

Table 1. Glycosylation Site Occupancy

A. N-Linked Glycosylation

	No of PNG Sites	Occupancy
Pyro_QCVN ¹⁷ LTTR	1	1
FSN ⁶¹ VTWF	1	1
HAIHVSGTN ⁷⁴ GTK	1	1
TQSLLIVN ¹²² ATNVVVK/IVNN ¹²² ATNVVVK	1	1
HKN ¹⁴⁹ NKSWMESEF/N ¹⁴⁹ NK	1	1
VYSSANN ¹⁶⁵ CTFEYVSQPFLMDLEGK/SSANN ¹⁶⁵ CTF	1	1
DLPQGFSALEPLVDLPIGIN ²³⁴ ITR/SALEPLVDLPIGIN ²³⁴ ITR	1	1
YNEN ²⁸² GTITDAVDCALDPLSETK	1	1
FPN ³³¹ ITNLCPF/FPN ³³¹ ITNL	1	1
GEVFN ³⁴³ ATRF/ N ³⁴³ ATRF	1	1
GGVSVITPGTN ⁶⁰³ TSNQVAVLY	1	1
QDVN ⁶¹⁶ CTEVPVAIHADQLTPTWR/ QDVN ⁶¹⁶ CTEVPVAIHADQL	1	1
AGCLIGAEHV ⁶⁵⁷ NSYECDIPIGAGICASYQTQTNSPR/AGCLIGAEHV ⁶⁵⁷ NSY	1	1
SVASQSIIAYTMSLGAENSVAYS ^{N709} NSIAIPTN ⁷¹⁷ FTISVTTEILPVSMK/S ^{N709} NSIAIPTN ⁷¹⁷ F	2	2
DFGGFN ⁸⁰¹ FSQILPDPSKPSK/TPPIKDFGGFN ⁸⁰¹ FSQILPDPSKPSK	1	1
GYHLMSFPQSAPHGVVFLHVTYVPAQEK ^{N1074} FTTAPAICHDGK / N ¹⁰⁷⁴ FTTAPAICHDGK / VPAQEK ^{N1074} F	1	0 and 1
EGVFVS ^{N1098} GTHWFVTQR/VFVS ^{N1098} GTHW	1	1
VSGNCDVVIGIVN ¹¹³⁴ NTVY	1	1
N ¹¹⁵⁸ HTSPDVLGDISGIN ¹¹⁷³ ASVVNIQK	2	2
NLN ¹¹⁹⁴ ESLIDLQELGK	1	1

B. O-Linked Glycosylation

	No of O-linked Sites	Occupancy
VQPT ³²³ ES ³²⁵ IVR	2	0 and 1
AGCLIGAEHVNN ^{S659} YECDIPIGAGICAS ⁶⁷³ YQT ⁶⁷⁶ Q T ⁶⁷⁸ NS ⁶⁸⁰ PR	5	0,1 and 2
T ⁶⁹⁶ MSLGAENSVAY	1	0 and 1
NHT ¹¹⁶⁰ SPDVLGDIS ¹¹⁷⁰ GINASVVNIQK	2	0 and 1

Table 2. SARS-CoV-2 S Glycoprotein Natural Variants

	Disulfide Bond Partner	Location	Processing	Subunit Association	Infectivity (VSVΔG)
WT	NA	NA	++++	++++	++++
C15F	C136	Within NTD (S1)	+++	++++	+++
C301F	C291	Within NTD (S1)	-	NA	++
C379F	C432	Within RBD (S1)	-	NA	++
T323I	NA	NTD-RBD junction	++++	++	+++
S673I	NA	CTD2 of S1	++	++++	+
T676I	NA	CTD2 of S1	++++	+++	++++
S1170F	NA	HR2 of S2	+++	+++	++++